In-silico clinical pharmacology and differential biophysics.
Simulate drug interactions, organ failure and therapeutic windows in real time. Built for pharmacy and medical students, clinicians and researchers.
Total ibrutinib exposure over 48 hours, compared with ibrutinib alone.
Clarithromycin blocks the liver enzyme that clears ibrutinib, so the drug builds up in the blood.
Ibrutinib in plasma (ng/mL)
What you can model.
Every curve comes from the same engine.
Drug interactions
See how one drug blocks or speeds up the clearance of another.
Organ function
Change kidney and liver function, pregnancy, burns or fever and watch exposure adapt.
Safety thresholds
Follow receptor binding against efficacy floors and side-effect ceilings.
From patient to a clear answer.
Every simulation follows the same three steps.
Patient and regimen
Drugs, doses, organ function and genetics.
Simulated physiology
Absorption, distribution, metabolism and elimination run together.
A clear answer
A plain-language summary and the size of the exposure change.
Grounded in primary evidence.
Calibrated on four kinds of clinical and biochemical data.
Human in vivo pharmacokinetics
Clearance, volume and half-life from official drug labels.
In vitro enzyme and receptor affinities
Measured binding and inhibition constants from human assays.
Pharmacogenomic dosing guidelines
Metabolizer phenotypes and genotype-guided dosing tiers.
Peer-reviewed clinical studies
Interaction and special-population trials in published literature.
Clinical scenarios.
Open a ready-made patient case in the simulator, then change anything.
Start from a clinical case or a blank regimen.